VERICEL CORP

VCELNASDAQ

🏆 #1587 by market capEarnings Nov 5US Equity

$44.32▲ $0.40 (+0.90%)

Market closed · at close

1h—

24h▲ 0.9%

7d▼ 2.2%

14d▼ 4.7%

30d▼ 6.7%

1y▲ 21.3%

🏦Market Cap

$2.26B

Small Cap

📈Revenue Growth (YoY)

+22.9%

Healthy

📊Gross Margin

74.6%

High

💵FCF Margin

20.1%

Strong

⚖️P/S Ratio

7.5x

Fair

Otter Score

Fair

Trading Snapshot

Day Range: $43.62 – $45.19
52-Week Range: $28.95 – $49.32
Volume: $1.86B
Avg Volume: $2.30B
Shares Outstanding: 51.1M
Next Earnings: Oct 28, 2026

Fundamentals Snapshot

Annual Revenue: $276M
Last Q Revenue: $77M
P/E Ratio: 94.6
P/S Ratio: 7.5x
EPS (TTM): $0.42
Dividend Yield: —

Why Investors Own VCEL

✓High-growth profile — revenue up +47.1% YoY with expanding US Equity exposure.
✓Healthy economics — 71% gross margin and 29% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$276M▲ +41.2% YoY

Gross Margin (TTM)

71.4%▲ +1.2% YoY

Operating Income (TTM)

$29M▲ +41.2% YoY

Free Cash Flow (TTM)

$79M▲ +41.2% YoY

About VERICEL CORP

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.

🦦